ArticleFrontiers in oncology2021

Serum Levels of Soluble Urokinase Plasminogen Activator Receptor Predict Tumor Response and Outcome to Immune Checkpoint Inhibitor Therapy.

Sven H Loosen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.